Literature DB >> 8755998

Maximal actomyosin ATPase activity and in vitro myosin motility are unaltered in human mitral regurgitation heart failure.

T T Nguyen1, E Hayes, L A Mulieri, B J Leavitt, H E ter Keurs, N R Alpert, D M Warshaw.   

Abstract

Myofibrillar but not actomyosin ATPase is depressed in failing myocardium from patients with dilated cardiomyopathy. Since there is a similar depression of myofibrillar ATPase in mitral regurgitation myocardium, we investigated whether or not the hydrolytic and mechanical performances of myosin are altered by comparing the maximal actomyosin ATPase activity and the in vitro myosin motility of myocardial myosin from patients with mitral regurgitation heart failure with that of patients with normal ventricular function. The results show that there is no significant difference (P > .05) between nonfailing and failing values for either the maximal actomyosin ATPase activity (0.3 s-1.head-1) or the myosin motility (1 micron/s). These observations suggest that changes, other than in the myosin heavy chain, contribute to the altered myocardial performance in mitral regurgitation myocardium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755998     DOI: 10.1161/01.res.79.2.222

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

1.  Kinetic differences at the single molecule level account for the functional diversity of rabbit cardiac myosin isoforms.

Authors:  K A Palmiter; M J Tyska; D E Dupuis; N R Alpert; D M Warshaw
Journal:  J Physiol       Date:  1999-09-15       Impact factor: 5.182

Review 2.  Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.

Authors:  Jarmila Machackova; Judit Barta; Naranjan S Dhalla
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

Review 3.  Thick filament proteins and performance in human heart failure.

Authors:  Bradley M Palmer
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

Review 4.  Functional consequences of sarcomeric protein abnormalities in failing myocardium.

Authors:  Martin M LeWinter
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

5.  Regulation of fibre contraction in a rat model of myocardial ischemia.

Authors:  Young Soo Han; Ozgur Ogut
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

6.  R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level.

Authors:  K A Palmiter; M J Tyska; J R Haeberle; N R Alpert; L Fananapazir; D M Warshaw
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

7.  Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function.

Authors:  Joachim P Schmitt; Edward P Debold; Ferhaan Ahmad; Amy Armstrong; Andrea Frederico; David A Conner; Ulrike Mende; Martin J Lohse; David Warshaw; Christine E Seidman; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

Review 8.  Tuning cardiac performance in ischemic heart disease and failure by modulating myofilament function.

Authors:  Sharlene M Day; Margaret V Westfall; Joseph M Metzger
Journal:  J Mol Med (Berl)       Date:  2007-03-30       Impact factor: 4.599

9.  Functional significance of cardiac myosin essential light chain isoform switching in transgenic mice.

Authors:  J G Fewell; T E Hewett; A Sanbe; R Klevitsky; E Hayes; D Warshaw; D Maughan; J Robbins
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

Review 10.  Thin filament remodeling in failing myocardium.

Authors:  Peter VanBuren; Yoko Okada
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.